Trials / Completed
CompletedNCT03098706
Therapeutic Hypothermia in "Expanded Criteria" Brain-dead Donors and Kidney-graft Function
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial" HYPOREME
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 532 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Each year, only one third of patients registered on the waiting list receive a kidney transplant. Numerous paths are being explored with the aim of reversing this shortage. The first is to increase the number of organs by developing harvesting from donors in a state of brain-death (BD) termed "expanded criteria donors" or from patients deceased from circulatory arrest. Another fundamental factor is to insure the success of the transplant by limiting the dysfunction of donor kidneys, marked by a delayed graft function (DFG). The development of techniques to insure correct perfusion of harvested organs, and the optimization of reanimation and intensive care of brain-dead donors constitute important factors in DGF reduction. Therapeutic Hypothermia could to be an attractive care strategy for BD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Procedure control: normothermia | Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C. |
| PROCEDURE | Procedure active | Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method. |
Timeline
- Start date
- 2017-11-08
- Primary completion
- 2022-03-21
- Completion
- 2022-03-21
- First posted
- 2017-04-04
- Last updated
- 2022-06-21
Locations
54 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03098706. Inclusion in this directory is not an endorsement.